Linifanib (ABT-869) is a structurally novel, potent RTK and VEGF and PDGF receptor families inhibitor with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-¦Â, KDR, and CSF-1R, respectively. It has much less activity (IC50s > 1 ¦ÌM) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. In vivo ABT-869 is effective orally in the mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis ( >50%inhibition, 15 mg/kg ).

June 21, 2017

prudect name : Linifanib (ABT-869) is a structurally novel, potent RTK and VEGF and PDGF receptor families inhibitor with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-¦Â, KDR, and CSF-1R, respectively. It has much less activity (IC50s > 1 ¦ÌM) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. In vivo ABT-869 is effective orally in the mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis ( >50%inhibition, 15 mg/kg ).
Linifanib abt869

Synonyms: Linifanib ABT-869CAS NO: 796967-16-3Molecular Formula: C₂₁H₁₈FN₅OMolecular Weight: 375.40Purity: 98% minSolubility: In DMSOStorage: −20°C

XL184 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18523006